Evidence map›Paper›PMID 38359148›Full record

ArticleCancer research2024

Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling.

Ruyi Zhang, Shanshan Li, Kelly Schippers, Yunlong Li, Boaz Eimers, Marla Lavrijsen, Ling Wang, Guofei Cui, Xin Chen, Maikel P Peppelenbosch and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ruyi ZhangDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0004-0752-7179
Shanshan LiDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-0988-6592
Kelly SchippersDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0000-0200-1048
Yunlong LiDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-0115-9342
Boaz EimersDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0004-4797-079X
Marla LavrijsenDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0001-3341-7780
Ling WangDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0007-6314-9776
Guofei CuiCancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.ORCID 0009-0005-5624-0403
Xin ChenCancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.ORCID 0000-0002-9588-0164
Maikel P PeppelenboschDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-9112-6028
Joyce H G LebbinkDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-6240-2895
Ron SmitsDepartment of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6798-3206
Erasmus MC Cancer Institute · NLCancer Center of Hawaii · USErasmus MC · NL

Funding

Investigating Multifactorial Beta-catenin Activation in Hepatocellular CancersR01CA250227 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Xin Chen, Satdarshan Singh Monga · 2021 to 2026
$3.0M
China Scholarship Council (CSC) 201808530490China Scholarship Council (CSC) 201909370083NCI NIH HHS R01 CA250227
6 · The paper itself

Abstract

AXIN1 is a major component of the β-catenin destruction complex and is frequently mutated in various cancer types, particularly liver cancers. Truncating AXIN1 mutations are recognized to encode a defective protein that leads to β-catenin stabilization, but the functional consequences of missense mutations are not well characterized. Here, we first identified the GSK3β, β-catenin, and RGS/APC interaction domains of AXIN1 that are the most critical for proper β-catenin regulation. Analysis of 80 tumor-associated variants in these domains identified 18 that significantly affected β-catenin signaling. Coimmunoprecipitation experiments revealed that most of them lost binding to the binding partner corresponding to the mutated domain. A comprehensive protein structure analysis predicted the consequences of these mutations, which largely overlapped with the observed effects on β-catenin signaling in functional experiments. The structure analysis also predicted that loss-of-function mutations within the RGS/APC interaction domain either directly affected the interface for APC binding or were located within the hydrophobic core and destabilized the entire structure. In addition, truncated AXIN1 length inversely correlated with the β-catenin regulatory function, with longer proteins retaining more functionality. These analyses suggest that all AXIN1-truncating mutations at least partially affect β-catenin regulation, whereas this is only the case for a subset of missense mutations. Consistently, most colorectal and liver cancers carrying missense variants acquire mutations in other β-catenin regulatory genes such as APC and CTNNB1. These results will aid the functional annotation of AXIN1 mutations identified in large-scale sequencing efforts or in individual patients. SIGNIFICANCE: Characterization of 80 tumor-associated missense variants of AXIN1 reveals a subset of 18 mutations that disrupt its β-catenin regulatory function, whereas the majority are passenger mutations.

Indexed as

Axin Proteinbeta CateninMutation, MissenseCell Line, TumorGlycogen Synthase Kinase 3 betaHEK293 CellsHumansLiver NeoplasmsNeoplasmsProtein BindingSignal TransductionAXIN1 protein, humanAxin Proteinbeta CateninCTNNB1 protein, humanGlycogen Synthase Kinase 3 beta

Identifiers

PMID38359148
PMCPMC11063763
OpenAlexW4391839352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.